No profile data available.
Global Cord Blood Corporation (CORBF) is a healthcare company in the additional medical testing equipment industry, based in Central, Hong Kong, with about 1,202 full-time employees.
It reported revenue of 1.24 billion CNY for fiscal year 2022, up 7.2% from fiscal year 2021, and net income of 501.07 million CNY. Its market capitalization was $140.61 million as of February 5, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2022; market data as of February 5, 2026.
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.
Global Cord Blood reported 1.24 billion CNY in revenue for fiscal year 2022, up 7.2% from 1.16 billion CNY in fiscal year 2021.
$140.61 million as of February 5, 2026.
Listed companies of a similar size in the same industry (additional medical testing equipment) include Bio-Rad Laboratories, Inc. (BIO), QuidelOrtho Corporation (QDEL), Exagen Inc. (XGN), Biomerica, Inc. (BMRA).